A study suggests GST-HG141 may become an effective new hepatitis B treatment for patients with incomplete response to current antiviral therapies.
A study shows spironolactone reduces fatty liver risk in patients with hypertension, lowering liver fat accumulation and slowing fibrosis progression.
Autoimmune hepatitis incidence has increased notably in older adults, with higher prevalence and better treatment response, often presenting with milder symptoms.
Orforglipron, an oral GLP-1 small molecule, shows significant weight loss results and may become an alternative to injectable drugs like Ozempic or Wegovy.
Hydronidone has demonstrated significant reversal of liver fibrosis in patients with chronic hepatitis B, offering a potential new therapeutic option.
HU6 is a novel oral drug that reduces liver fat and body weight through controlled metabolic acceleration, showing promising results in clinical trials compared to placebo.
A large study shows that daily alcohol consumption, even in small amounts, worsens liver fibrosis in patients with metabolic liver disease.
A large study reveals that vitamin E can reduce liver fibrosis and improve liver health in patients, reinforcing its therapeutic value alongside diet and exercise.
Infliximab shows positive results in autoimmune hepatitis resistant to conventional therapies, improving liver function in most patients and representing a potential future treatment option.
Women with early menarche show a higher risk of fatty liver disease. Later onset lowers this risk, highlighting the importance of monitoring weight and liver health.